News | Contrast Media | July 03, 2023

Preferential use of pulmonary MR angiography (MRA) for diagnosing pulmonary embolus (PE) in the general population helped conserve iodinated contrast media during the 2022 shortage 

Preferential use of pulmonary MR angiography (MRA) for diagnosing pulmonary embolus (PE) in the general population helped conserve iodinated contrast media during the 2022 shortage

Patient was found to have deep vein thrombosis. Gadolinium-enhanced MRA was performed to assess for pulmonary embolus (PE). Coronal contrast-enhanced T1-weighted images in pulmonary arterial phase (A) and low flip-angle delayed phase (B) show PE (arrows, A and B). Delayed-phase image also shows cardiac chamber (star) and ascending thoracic aorta (chevron). Multiphase acquisition of MRA during inflow and outflow of contrast agent from pulmonary arteries is in distinction to single acquisition of CTA and may facilitate obtaining optimal enhancement of pulmonary arteries. Image courtesy of AJR 


July 3, 2023 — According to an accepted manuscript published in ARRS’ own American Journal of Roentgenology (AJR), preferential use of pulmonary MR angiography (MRA) for diagnosing pulmonary embolus (PE) in the general population helped conserve iodinated contrast media during the 2022 shortage. 

“This single-center experience demonstrates use of pulmonary MRA as a practical substitute for pulmonary CTA in emergency settings,” concluded lead investigator Jitka Starekova, MD, from the radiology department of the University of Wisconsin in Madison.   

Starekova et al.’s study included all CTA and MRA examinations performed to exclude PE at their large academic medical center (University of Wisconsin-Madison Hospital and Clinics) from April 1 through July 31 (18 weekly periods) in:   

2019 (before the COVID-19 pandemic and contrast media shortage), 

2021 (during the pandemic, though before the shortage), 

2022 (during both the pandemic, as well as the shortage). 

To help preserve iodinated contrast media, from early May through mid-July of 2022, MRA served as the preferred test for PE diagnosis. Upon reviewing CTA and MRA reports, Starekova and her AJR colleagues estimated iodinated contrast media savings via preferential MRA usage. 

Ultimately, preferred use of pulmonary MRA to diagnosis PE among the general population conserved (from April 1 to July 31, 2022) an estimated 27 liters of iohexol (Omnipaque) 350mg/ml. During weeks 8-11, more MRA examinations (range, 45-63) than CTA examinations (range, 27-46) were performed. 

Noting their AJR accepted manuscript evaluated MRA for PE diagnosis in “an all-comer real-world setting,” the present study also includes a larger sample size in comparison to previous research. 

For more information: www.arrs.org


Related Content

News | Cardiac Imaging

May 17, 2024 — The Cum Laude Award-Winning Online Poster presented during the 124th ARRS Annual Meeting found that the ...

Time May 17, 2024
arrow
News | Artificial Intelligence

May 15, 2024 — Heart disease is the leading cause of mortality in the U.S., accounting for one out of every five deaths ...

Time May 15, 2024
arrow
News | Pediatric Imaging

May 15, 2024 — Transfer learning (TL) models trained on heterogeneous public datasets and fine-tuned using institutional ...

Time May 15, 2024
arrow
News | Radiology Business

May 14, 2024 — University Hospitals (UH) and Siemens Healthineers announce a 10-year strategic alliance that builds on ...

Time May 14, 2024
arrow
News | Prostate Cancer

May 13, 2024 — Avenda Health, an AI healthcare company creating the future of personalized prostate cancer care, unveils ...

Time May 13, 2024
arrow
News | Radiology Imaging

May 13, 2024 — National Basketball Association (NBA), the National Basketball Players Association (NBPA), and the Next ...

Time May 13, 2024
arrow
News | Breast Imaging

May 10, 2024 — According to the Summa Cum Laude Award-Winning Online Poster presented during the 124th ARRS Annual ...

Time May 10, 2024
arrow
News | Contrast Media

May 8, 2024 — Swedish biotech company Ascelia Pharma AB has announced that its liver imaging drug candidate, Orviglance ...

Time May 08, 2024
arrow
News | Magnetic Resonance Imaging (MRI)

May 7, 2024 — The Magna Cum Laude Award-Winning Online Poster presented during the 124th ARRS Annual Meeting showed a ...

Time May 07, 2024
arrow
News | Treatment Planning

May 6, 2024 — Elekta announced the acquisition of Philips Healthcare’s Pinnacle Treatment Planning System (TPS) patent ...

Time May 06, 2024
arrow
Subscribe Now